Log in

NASDAQ:AKAOAchaogen Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range
$0.11
MA: $0.11
$0.11
52-Week Range N/A
VolumeN/A
Average Volume3.34 million shs
Market Capitalization$7.03 million
P/E RatioN/A
Dividend YieldN/A
Beta0.78
Achaogen, Inc., a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.
Read More
Achaogen logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.77 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AKAO
CUSIPN/A
Phone650-800-3636

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.73 million
Book Value($0.13) per share

Profitability

Net Income$-186,510,000.00
Net Margins-2,136.94%

Miscellaneous

Employees206
Market Cap$7.03 million
Next Earnings DateN/A
OptionableOptionable

Receive AKAO News and Ratings via Email

Sign-up to receive the latest news and ratings for AKAO and its competitors with MarketBeat's FREE daily newsletter.

Achaogen (NASDAQ:AKAO) Frequently Asked Questions

How were Achaogen's earnings last quarter?

Achaogen Inc (NASDAQ:AKAO) issued its earnings results on Monday, August, 6th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.92) by $0.19. The biopharmaceutical company earned $2.56 million during the quarter, compared to the consensus estimate of $1.49 million. Achaogen had a negative return on equity of 357.49% and a negative net margin of 2,136.94%. View Achaogen's earnings history.

Has Achaogen been receiving favorable news coverage?

News articles about AKAO stock have been trending very negative on Tuesday, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Achaogen earned a news sentiment score of -3.2 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Achaogen.

Who are some of Achaogen's key competitors?

What other stocks do shareholders of Achaogen own?

Who are Achaogen's key executives?

Achaogen's management team includes the following people:
  • Mr. Blake Wise, CEO & Director (Age 48)
  • Mr. Gary Loeb, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 49)
  • Ms. Zeryn Sarpangal, CFO and Principal Financial & Accounting Officer (Age 39)
  • Ms. Elizabeth Bhatt, Chief Bus. Officer & COO (Age 50)
  • Ms. Jeannie Lloyds, VP of Sales

What is Achaogen's stock symbol?

Achaogen trades on the NASDAQ under the ticker symbol "AKAO."

How big of a company is Achaogen?

Achaogen has a market capitalization of $0.00 and generates $8.73 million in revenue each year. The biopharmaceutical company earns $-186,510,000.00 in net income (profit) each year or ($3.70) on an earnings per share basis. Achaogen employs 206 workers across the globe.

What is Achaogen's official website?

The official website for Achaogen is www.achaogen.com.

How can I contact Achaogen?

Achaogen's mailing address is 1 TOWER PLACE SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-800-3636 or via email at [email protected]

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.